Clinical Data StrengthImetelstat-treated patients demonstrated significantly higher rates of durable RBC-TI attainment, highlighting the drug's efficacy and potential for improving patient quality of life.
Leadership And Investor EngagementGeron's leadership, represented by Chairperson & CEO John (Chip) Scarlett, actively participated in the Needham Healthcare Conference, indicating proactive engagement with investors and analysts.
Regulatory MilestoneThe FDA AdCom panel voted 12-2 in favor that the benefits of imetelstat outweigh the risks, a strong indicator of the drug's potential for approval.